Home
    • Plans Blog Contact
    Kiora Pharmaceuticals Inc logo

    Kiora Pharmaceuticals Inc

    KPRX
    Last price US$2.53
    Market cap US$10.1m
    12M price change -17.86%
    Loading the 12-month Mave Thesis and 1-month news signal

    Industry and sector peers, plus broader research alternatives

    View comparison
    PharmaCyte Biotech IncPMCB Industry peer Abcam PLCABCM Industry peer RVL Pharmaceuticals PLCRVLP Industry peer Zoetis IncZTS Sector peer
    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    Kiora Pharmaceuticals Inc Overview

    Industry: Pharmaceuticals

    Sector: Healthcare

    Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, as well as for treating non-infectious posterior uveitis; and KIO-201, an eye drop, which is in Phase 3 clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair after refractive surgery. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California. Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts Read More

    Mavefund brings filings, fundamentals, valuation, price history and news for Kiora Pharmaceuticals Inc into one research view. The sections below show what strengthens or weakens the research case.

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed May 08, 2026

    Quarterly result summary

    Revenue was $1.2M (+0% YoY). Net loss was -$2.4M.

    Revenue $1.2M +0% YoY
    Net loss -$2.4M reported

    What changed

    • Revenue +0% YoY to $1.2M.

    Guidance / outlook

    we expect will enable advancement to the higher dose cohort.

    Earnings release Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing 8-K May 08, 2026 SEC filing 10-Q May 08, 2026 SEC filing 10-K Mar 25, 2026 Earnings release Earnings release Mar 25, 2026 SEC filing 8-K Mar 25, 2026 SEC filing 10-Q Nov 07, 2025 SEC filing 8-K Nov 07, 2025 Earnings release Earnings release Nov 07, 2025 Earnings release Earnings release Aug 08, 2025 SEC filing 8-K Aug 08, 2025 SEC filing 10-Q Aug 08, 2025

    Prediction-grade evidence

    Recent News

    Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

    No qualified company news in the last 14 days

    No recent article passed both the company-relevance and source-reliability checks. Research continues to use the other available filings, fundamentals, market data, and valuation inputs.

    Earnings Per Share

    Score 5.00/5
    Kiora Pharmaceuticals Inc boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Pharmaceuticals industry , PharmaCyte Biotech Inc , Abcam PLC , RVL Pharmaceuticals PLC are companies with high ratings.

    Return on Equity

    Score 0.52/5
    Kiora Pharmaceuticals Inc exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Kiora Pharma... KPRX US$10.1m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 1.18/5
    Kiora Pharmaceuticals Inc olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Kiora Pharma... KPRX US$10.1m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Pharmaceuticals industry , PharmaCyte Biotech Inc , Abcam PLC , RVL Pharmaceuticals PLC are companies with high ratings.

    Leverage

    Score 2.52/5
    Kiora Pharmaceuticals Inc attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc , also exhibit high scores.
    Kiora Pharma... KPRX US$10.1m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    Verified SEC statements load when this section enters view.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    Kiora Pharmaceuticals Inc logo

    Kiora Pharmaceuticals Inc

    US$2.53

    US$10.1m

    -1.94%

    -17.86%